[A reserve chemotherapy for Hodgkin's disease (author's transl)].
In 22 patients suffering from Hodgkin's disease with visceral lesions resistant to MOPP chemotherapy, the authors have tried a reserve treatment combining adriamycin, vinblastin, bleomycin and DTIC ("ABVD therapy"). On day 1 patients were given a one-hour infusion of DTIC 200 mg with adriamycin 40 mg and vinblastin 10 mg. This was followed 3 to 6 hours later by bleomycin 15 mg i. m. On days 2, 3 and 4, DTIC 200 mg was infused alone, and a treatment similar to that of day 1 but without DTIC was repeated on day 15. There were six courses of treatment altogether. The patients were followed-up for 6 to 24 months. Complete remission without relapse was obtained in 32% of the cases.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin
Maladie de Hodgkin. Possibilité d'une chimiothérapie de secours après échec du traitement classique.